Esperion Therapeutics (ESPR) Projected to Post Earnings on Tuesday

Esperion Therapeutics (NASDAQ:ESPR) will likely be announcing its earnings results before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $61.58 million for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Esperion Therapeutics Trading Up 2.4 %

ESPR stock opened at $1.70 on Friday. The firm has a market capitalization of $334.96 million, a PE ratio of -2.66 and a beta of 1.01. Esperion Therapeutics has a one year low of $1.58 and a one year high of $3.94. The firm has a 50-day moving average of $2.02 and a two-hundred day moving average of $2.09.

Wall Street Analysts Forecast Growth

ESPR has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. JMP Securities reaffirmed a “market outperform” rating and issued a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. Needham & Company LLC reissued a “buy” rating and set a $6.00 price objective on shares of Esperion Therapeutics in a report on Friday, December 13th. Cantor Fitzgerald started coverage on Esperion Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price objective for the company. Finally, The Goldman Sachs Group started coverage on Esperion Therapeutics in a research note on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $6.75.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.